Chapel Hill

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Source

• Recruiting

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· Phase 3· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· Source

• Recruiting

  Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  NCT07155226· Phase 1/2· Source

• Recruiting

  A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· Phase 1/2· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· Source

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Source

• Recruiting

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

  NCT06916806· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

  NCT06897930· Phase 1/2· Source

• Active, not recruiting

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· Phase 2· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· Source

• Active, not recruiting

  A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

  NCT06040099· Phase 2· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· Phase 3· Source

• Active, not recruiting

  Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

  NCT05644561· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Source

• Active, not recruiting

  A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

  NCT04556773· Phase 1· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

  NCT04512235· Phase 3· Source

• Active, not recruiting

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma3 recruiting
• Heart failure2 recruiting
• Lupus (SLE)2 recruiting
• Rheumatoid arthritis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Kidney cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

  NCT06299826· Phase 2· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· Source

• Completed

  Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

  NCT05329194· Phase 4· Source

• Terminated

  Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

  NCT05218096· Phase 2· Source

• Completed

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· Phase 2/3· Source

• Completed

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· Phase 4· Source

• Completed

  A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

  NCT03759366· Phase 3· Source

• Completed

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· Source